NEW YORK, March 2 (GenomeWeb News) - Dharmacon will supply Bayer Pharmaceuticals with siRNA reagents for 4,000 gene targets by the end of March, the company said today.
The agreement expands an existing contract the companies announced in November. Bayer plans to use the custom siRNA reagents for internal target validation research.
Last month, Fisher Scientific International said it will acquire Lafayette, Colo.-based Dharmacon for $80 million in cash.